Eli Lilly and Company $LLY Holdings Boosted by Middleton & Co. Inc. MA

Middleton & Co. Inc. MA raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 4.7% during the 4th quarter, Holdings Channel.com reports. The firm owned 12,680 shares of the company’s stock after acquiring an additional 573 shares during the period. Eli Lilly and Company accounts for 1.4% of Middleton & Co. Inc. MA’s investment portfolio, making the stock its 22nd biggest position. Middleton & Co. Inc. MA’s holdings in Eli Lilly and Company were worth $13,627,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. First National Bank of Hutchinson boosted its position in shares of Eli Lilly and Company by 40.9% in the fourth quarter. First National Bank of Hutchinson now owns 2,148 shares of the company’s stock worth $2,308,000 after buying an additional 624 shares during the period. RMR Wealth Builders raised its position in Eli Lilly and Company by 5.7% during the fourth quarter. RMR Wealth Builders now owns 5,604 shares of the company’s stock valued at $6,023,000 after buying an additional 302 shares during the period. Anchyra Partners LLC purchased a new stake in Eli Lilly and Company in the 4th quarter worth about $2,411,000. Nippon Life Global Investors Americas Inc. boosted its position in Eli Lilly and Company by 1.0% during the 4th quarter. Nippon Life Global Investors Americas Inc. now owns 76,060 shares of the company’s stock worth $81,740,000 after acquiring an additional 780 shares during the period. Finally, New Hampshire Trust boosted its position in Eli Lilly and Company by 28.7% during the 4th quarter. New Hampshire Trust now owns 946 shares of the company’s stock worth $1,017,000 after acquiring an additional 211 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Earnings beat and guidance raise — Lilly reported Q1 revenue of $19.8B (up ~56% YoY) and non?GAAP EPS that topped estimates; management raised full?year 2026 revenue and EPS guidance. Lilly Q1 press release
• Positive Sentiment: GLP-1 sales are the growth engine — Mounjaro and Zepbound volumes drove huge top?line growth and analysts/Jim Cramer highlighted the large addressable weight?loss market as a multi?year tailwind. GLP-1 Sales Continue to Lift Eli Lilly
• Positive Sentiment: Regulatory move could limit compounded competitors — the FDA proposed excluding active ingredients in tirzepatide/semaglutide from the 503B bulks list, which would curb large?scale compounding of cheaper alternatives and support branded sales. FDA proposes excluding weight-loss drugs from compounding list
• Positive Sentiment: Foundayo pill early uptake — management said more than 20,000 people have started the newly launched oral GLP?1 pill, supporting upside potential for incremental sales beyond injections. More than 20,000 people are taking Eli Lilly’s weight loss pill
• Neutral Sentiment: Pipeline and tech partnerships — Lilly signed a multi?year ~$2.25B AI/genetics deal to advance recombinase-based gene editing, which is strategic for long?term growth but not immediately revenue?generating. Eli Lilly Signs Up To $2.25 Billion AI Gene Editing Deal
• Neutral Sentiment: Full earnings detail available — the Q1 earnings call transcript and slides give color on volume vs. price, channel mix and Foundayo expectations for investors who want to dig into the drivers. Eli Lilly Q1 2026 Earnings Call Transcript
• Negative Sentiment: Pricing pressure and lower realized prices — management noted strong volume but lower realized prices for GLP?1s partially offset revenue growth; sustained price erosion would limit margin upside. FT: Lilly profits more than double as weight-loss drug sales soar
• Negative Sentiment: Competition and generics risk — approvals of generic GLP?1s abroad and mixed early social?data on Foundayo vs. peers create execution and share?loss risk that investors should monitor. LLY falls as Canada approves generic weight-loss drugs

Eli Lilly and Company Stock Performance

Shares of LLY opened at $937.04 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The company’s fifty day moving average is $947.05 and its 200-day moving average is $984.98. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The firm has a market cap of $885.33 billion, a price-to-earnings ratio of 40.83, a price-to-earnings-growth ratio of 1.00 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same period last year, the business posted $3.34 EPS. Eli Lilly and Company’s revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts expect that Eli Lilly and Company will post 33.79 EPS for the current fiscal year.

Analysts Set New Price Targets

LLY has been the topic of a number of research reports. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Tuesday, March 10th. Rothschild & Co Redburn boosted their price objective on shares of Eli Lilly and Company from $875.00 to $880.00 and gave the company a “neutral” rating in a research report on Friday, April 10th. Leerink Partners dropped their price objective on shares of Eli Lilly and Company from $1,296.00 to $1,058.00 and set an “outperform” rating on the stock in a research note on Monday. Zacks Research downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Finally, Loop Capital set a $1,200.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, February 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,216.52.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.